Search Immortality Topics:

Page 6«..5678..2030..»


AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update – Business Wire

Posted: August 14, 2020 at 5:44 pm

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.

AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem), for ImStem to utilize AgeXs ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.

We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology, said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.

AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.

AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far, said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.

Q2 Highlights

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.

Staff Reductions

In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Second Quarter 2020 Operating Results

Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

June 30,2020

December 31,2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,033

$

2,352

Accounts and grants receivable, net

235

363

Prepaid expenses and other current assets

836

1,339

Total current assets

2,104

4,054

Excerpt from:
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire

Recommendation and review posted by G. Smith

Bill and Ted Comics Suggest That Rufus Is Actually The True Great One – Screen Rant

Posted: August 14, 2020 at 5:44 pm

A Bill and Ted comic suggest that for all his help and motivation, George Carlin's Rufus is the true Great One of the future instead of Bill and Ted.

In Bill and Ted's Excellent Adventure, we learn that Bill S. Preston, Esq and Ted "Theodore" Logan are destined to be the Two Great Ones who will usher in a golden age of humanity based on their music and philosophy. One of those citizens named Rufus, portrayed by the late actor and comedian George Carlin, is tasked with going back in time and ensuring Bill and Ted pass their history class, thus keeping the timeline intact. Rufus would return to assist Bill and Ted more than once and his faith and intervention, according to one Bill & Ted comic series, would suggest that Rufus is the true Great One instead of the iconic laidback duo.

In the Excellent Adventure, Rufus arrives at San Dimas in 1988 in the Circle K parking lot where he introduces himself to the freaked outBill and Ted whose doubts are put to rest when they meet themselves from a few hours in the future who vouch for Rufus' authenticity. Rufus explains to them how the time machine, in the shape of a telephone booth, works and any important instructions they should keep in mind but will most likely forget. Rufus doesn't show up again until the end when he brings along Bill and Ted's medieval love interests, removed from their arranged marriage and reunited with Bill and Ted so they can fulfill their destiny in Wyld Stallyns according to Rufus. In Bogus Journey, Rufus opposes Chuck De Nomolos' plan to rewrite history by sending murderous robot duplicates of the historical duo back in time. Hitching a ride, Rufus arrives in San Dimas earlier than expected and disguises himself as Ms. Wardroe who is in charge of the San Dimas Battle of the Bands. Making sure Wyld Stallyns is in the competition, Rufus reveals himself and his role in the drama after Bill and Ted defeat their heinous doppelgangers and their master De Nomolos. Never wavering in his faith, Rufus' patience and hard work pays off when Bill and Ted accomplish their destiny with music that seemingly unites the world.

RELATED:Bill and Ted Already Faced The Music In Amazing Comic Book Series

In Bill and Ted's Triumphant Return, a comic series by Brian Lynch, Jerry and Penelope Gaylord, intended to be the long-awaited third sequel- Bill and Ted have traveled to the future in hopes of curing their writer's block by "borrowing" their then-historical music and bringing it back to their present. Sidetracked in San Dimas 2645 with a mission to "Rufus" an ostracized and ridiculed young Chuck De Nomolos, the future Great Ones vow to teach Chuck how to play guitar in hopes of changing his nefarious ways. It is here, in the historic San Dimas High School, that a school report by De Nomolos' crush Claudia suggests that Rufus is actually the true Great One due to all of his assistance with Bill and Ted and that it was Rufus' idea to customize all the abandoned phone booths into time machines, which certain extraterrestrials got the idea to do with British police booths.

Although Bill and Ted get immortalized as the Two Great Ones, hopefully, Rufus gets his fair share of immortality for his role in that masterpiece for his faith in those two remained unbreakable.In the series when De Nomolos is given the opportunity to twist and rewrite history so he inherits all of Bill and Ted's power which leaves Rufus unemployed and a failure, he still manages to appear and inspire Bill and Ted to set things right despite the twisted and depressing future they find themselves in. Although Rufus won't reappear in the upcoming Bill and Ted: Face the Music, we're glad to hear that the late George Carlin will somehow make a cameo in the film. Although this comic series has been deemed non-canonical along with the other comic and television-related series, it's just good to see someone give credit where credit is due. One can only imagine what Bill and Ted, and essentially human history, would have been like if Rufus didn't appear in that Circle K parking lot all those years ago. It would have been most heinous, indeed. Last but not least to Rufus and George Carlin, youare missed and you truly were one of the greatest...

NEXT:Watch Keanu Reeves & Alex Winter's Bill & Ted Audition Tapes

The Avengers Are About To Face The PHOENIX FORCE

Drew is a reader, writer, artist, and creative professional based in Westchester, New York. He dabbles into cosplay, movie references, comics, and some anime while also being a Ghostbuster. He has a Bachelors in History, a Masters in Publishing and is excited to be working with Screen Rant. Previously his articles have been featured on Comic Book Resources and Iron Age Comics and he's excited to see what happens next!

Read the original post:
Bill and Ted Comics Suggest That Rufus Is Actually The True Great One - Screen Rant

Recommendation and review posted by G. Smith

It Was Run by Crooks Now It’s Bigger Than AI – Energy & Capital

Posted: August 14, 2020 at 5:44 pm

What's your biggest fear?

Snakes? Spiders? Sharks?

Heights? Clowns? Airplane crashes?

Public speaking? Heart Disease? Wolverines?

Think of your biggest fear and hold it in your mind for a moment.

(And email me if your greatest fear is in fact wolverines... because I have a lot of questions, beginning with why you are around wolverines in the first place.)

Whatever you're thinking of right now can most likely be boiled down to the fear of one of two things: death or suffering.

What I mean is people generally aren't afraid of snakes as much as they're afraid of the snake bite. The bite does all the damage to cause suffering and, maybe in rare cases, death.

In the same way, people aren't necessarily afraid of public speaking as much as they're afraid of making mistakes when speaking publicly thus suffering from embarrassment.

Likewise, if I had to guess, an individual wouldn't be as afraid of wolverines as he'd be afraid of what wolverines might (and probably will) do to him like claw up his leg and bite his neck. That's... quite undesirable.

Rare sighting of a wolverine in Washington state earlier this yearImage credit: istockphoto.com/Alphotographic

If you asked me my greatest fear, I'd tell you heights. I can't even watch a video of someone standing precariously high without my chest tightening and my palms sweating.

But it's really not the elevation that makes me nervous it's not even falling off. What's really got me worried is the sudden stop at the bottom. It's not the drop. It's the plop.

All this is to say most (if not all) of our fears generally have layers. And at the core of most of our fears are death and suffering.

But here's the rub...

And you know where this is going...

Suffering and death are inevitable parts of life. Every human being that has ever walked the Earth has experienced both.

That's where we find a dilemma that's been haunting humanity forever: No one wants to suffer. No one wants to die. But everyone must experience both.

As a result, there is (and always has been) a massive demand for methods to alleviate those fears. From philosophy to pharmaceuticals, humans have spent an unimaginable amount of time and resources softening fears of suffering and death. Let's just consider anti-aging cosmetics for a moment...

You could argue there is some philosophy that doesn't exactly aim to alleviate fears of aging and death. And of course, pharmaceuticals have a wide variety of purposes. But there's no inferring what cosmetic companies are trying to sell consumers with anti-aging products: beauty and youth. It's right in the name "anti-aging."

The Best Free Investment You'll Ever Make

Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.

You'll also get our free report, The (Safest) Way to Invest in Biotech.

The desire for beauty and youth is most often pinned on societal pressure. But I'd argue part of that desire is also one of many ways people use to alleviate the fear of death. If you look younger in the mirror and maybe even feel younger as a result, it's easier to convince yourself you're that much further away from death.

The global anti-aging cosmetics market is huge. In 2018 it was estimated to be worth over $50 billion. That's bigger than the AI market today. In fact, that's about the same size as the global solar energy market!

And the anti-aging cosmetics market is only estimated to grow from here. Forecasts estimate the global market will grow by about 5% or 6% CAGR over the next decade. And cosmetics are really just one small part of the growing anti-aging market.

For centuries, anti-aging practices were mostly relegated to the work of charlatans. More recently, the cosmetics industry took over. But new research into genetics and aging have allowed biogerontology (the real study of the biological basis of aging and age-related diseases) to flourish and gain legitimacy.

Anti-aging is becoming less snake oil and more real science. But there's something you should know...

This new research isn't working toward human immortality. I'm sorry, but you're never going to live forever. Nevertheless, new breakthroughs in anti-aging technology do promise to make you healthier and live longer. As my colleague Jeff Siegel says, anti-aging technology (despite the name) won't produce a Fountain of Youth. But it will produce a fountain of health.

For the past several months, Jeff has been studying the anti-aging market and the real science behind age-extending, groundbreaking biotechnologies. And he's come up with some really unique opportunities and ideas that I don't think most people have really considered. To read more about Jeff's recent research, click here.

Again, we're not talking about immortality. Instead, we're talking about significantly extending the human life span. And the truth is that's been happening over the course of thousands of years. Prior to the 20th century, the average global life expectancy for a human being was under 40 years old. In the past 100 years alone, new developments and better technology have increased life expectancy past 70. That's an 80% increase in about 100 years.

So we're not talking about science fiction here. Biotechnology has greatly extended our lives already. But it's not done. And the next phase of development in the field of biogerontology could be the key to continued life extension.

Check out Jeff's research. It's very easy to be skeptical about anti-aging technology. That's understandable. As I mentioned, for most of human history the market has been controlled by snake oil salesman and cosmetic marketing. But there is some real science behind the biological basis of aging and age-related disease that can be addressed with new research. Take a look at one of Jeff's most recent reports on anti-aging technology here.

I guarantee there are no wolverine attacks involved.

Until next time,Luke Burgess

As an editor at Energy and Capital, Lukes analysis and market research reachhundreds of thousands of investors every day. Luke is also a contributing editor of Angel Publishings Bull and Bust Report newsletter. There, he helps investors in leveraging the future supply-demand imbalance that he believes could be key to a cyclical upswing in the hard asset markets. For more on Luke, go to his editors page.

Trillions will be spent to secure the world's energy supply over the next two decades...and all sources are on the table. Oil, natural gas, solar, wind. There will be money made. Follow the money trail. Sign up for Energy and Capital now - it's entirely free!

We never spam! View our Privacy Policy

After getting your report, youll begin receiving the Energy and Capital e-Letter, delivered to your inbox daily.

Read the original post:
It Was Run by Crooks Now It's Bigger Than AI - Energy & Capital

Recommendation and review posted by G. Smith

Productive MLB pitcher Mike Leake has VC ties (Part 2 of 2) – Valley Roadrunner

Posted: August 14, 2020 at 5:44 pm

Part II of II parts. (Part I here)

Writers Note This is part two of a story on one-time Valley Center ballplayer Mike Leake.

So began an odyssey that would see Leake do some serious moving around, playing for a total of four teams in as many years.

Leakes stay in the Bay Area proved to be brief and not all that satisfying as he mustered only two wins in seven decisions.

Taking full advantage of his commendable body of work, Leake was able to sign a lucrative five-year $80 million dollar contract in December of 2015 with one of baseballs iconic franchises, the St. Louis Cardinals. Assigned a number 8 jersey like hed donned at ASU, Mike was hoping to replicate some similar good vibes but alas, it didnt work out that way.

During his first season in the River City, Leake struggled somewhat, registering just a 9-12 ledger that wasnt helped by a career high 4.69 ERA. He did manage to experience a meaningful achievement, however, when he fanned 10 batters in consecutive starts.

Better still, it appeared that his fortunes as a Card were definitely trending upward when he got off to a bag-up beginning in 17, carving out a 5-2 record and a spiffy 1.91 ERA in his first nine starts. But then it was as if he ran smack dab into a wall. From May 29 until late August, Leakes level dropped off noticeably and he was destined to lose 10 of his next 12 starts.

And so in a transaction not all that unexpected, the Redbirds swapped Leake to the Seattle Mariners in late August. Perhaps energized by the prospect of pitching for the team that he rooted for as a youngster, Leake bested Oakland in his first start for the Ms and finished the season strong, going 3-1 (2.53 ERA) in five outings with his new club.

For most of the next two campaigns, Leake was what hes almost always been, a tried-and-true performer, making 53 starts and nailing down 19 wins. The 5-10, 165-pound hurler also experienced a very close brush with baseball immortality. On July 19 in a contest against the Los Angeles Angels, Mike took a perfect game into the final frame, a mere three outs from forever etching his name into baseball lore. But alas, leadoff hitter Luis Rengifo pulled a groundball single into right field that ended all the drama and suspense. Leake would go on to pitch a complete game shutout but coming so close to accomplishing something so rare had to have been bittersweet.

Just over a month laterthanks to a deadline tradeLeake was packing his bags once more, this time heading back to Arizona where hed spent half his life. Fulfilling a dream to pitch for what he considered to be his hometown team, Mike was happy to return to the desert, which he claimed had a spirit to it.

Interestingly, Leake had been on the verge of signing with the Diamondbacks as a free agent in 2015 even though he wouldnt have collected near the cash he eventually received from the Cardinals. But a potential agreement with parameters already in place got scuttled when Arizona ownership balked and wouldnt pull the trigger on a deal.

So despite the fact that it had taken awhile, Leake was finally making his way back to the Valley of the Sun. From a family standpoint it couldnt have been a cozier arrangement since Leake resided in Paradise Valley with his wife and two children while both his parents and in-laws also had residences in Arizona.

As for the D-Backs, they valued Leakes consistency, durability, knack for throwing strikes and pitching to contact. And in his brief 10-game audition with Arizona, he demonstrated an adequate sampling of those skills while posting a 3-3 mark.

Going into the 2020 campaign, the veteran Leake was expected to compete for a back-end spot in the D-Backs rotation. But that never happened because Mike created a bit of a stir by becoming the first major leaguer to announce that he would be bypassing the shortened season due to concerns over COVID-19. After many heartfelt discussions and taking numerous factors into consideration, Leake decided to opt out. The facts suggest that this difficult decision was made primarily out of worry about the health and well-being of his close proximity family members and not himself.

Leake has indicated through his agent that he plans to return next season and looks forward to getting back on the mound in 2021, be that with the Diamondbacks or as a free agent if he is given a $5 million dollar buyout.

Over the years and throughout his career, Leake has often displayed varying looks, whether he was wearing a goatee or beard, was clean shaven, had closely cropped hair or favored long flowing locks that made him appear as if he were more surfer or radical than ballplayer. But one thing never changed. The guy always seemed to know what he was doing on the mound.

When Mike Leake first burst upon the prep baseball scene as an exceptionally promising and versatile athlete for the VC Jaguars, those that saw him knew he had the goods to standout but no one could be sure where it all might lead.

But Leakes path turned out to be a continuum from high school star, to collegiate great to consummate big league professional. And what a sturdy pro hes been. Over his lengthy career he has started 296 games, pitched 1,829 innings, won 105 contests and registered 1,231 strikeouts. Those are notable statistics not to be taken lightly. They reflect a pitcher whose rubber arm allowed him to answer the bell when called upon and regularly got results. They also speak to his uber dependability, staying power and competitiveness.

No matter the locale, wherever Mike Leake has pitched, he has generally done that place proud. Consider Valley Center lucky enough to be included among that fortunate group.

Visit link:
Productive MLB pitcher Mike Leake has VC ties (Part 2 of 2) - Valley Roadrunner

Recommendation and review posted by G. Smith

10 Of Rotten Tomatoes Worst of All Time That Are Surprisingly Watchable – Screen Rant

Posted: August 14, 2020 at 5:44 pm

There are a lot of terrible movies out there, yet, some movies are so bad that they transcend typical rating systems and actually become watchable.

Despite many film fans' insistence that "critics are always wrong," review aggregation site Rotten Tomatoes has become a make-or-break barometer of critical opinion surrounding movies. Films that receive the "Certified Fresh" rating oftentimes go on to big success, while anything labeled "Rotten" has to carry that distinction as a badge of shame in perpetuity.

RELATED: 10 Of The Worst 0% Horror Movies On Rotten Tomatoes

Recently, the good folks at Rotten Tomatoes compiled a 100 Worst of All Time list that's a whos-who of cinematic dumpster fires that should be sampled at one's peril. Still, there are a few guilty pleasures to be had in the list, and below we count down ten of Rotten Tomatoes' "worst of all time" that are surprisingly watchable, should you be brave enough to take the plunge!

After taking home the top disco dance prize in Saturday Night Fever, Staying Alive picks up six years later as Tony Manero (John Travolta) teaches young dancers at an NYC studio and yearns to make his way to Broadway. When he manages to score a backup dancing spot in a new production, he begins to backslide into his old, troubled behaviors.

Somehow, bizarrely, directed by Sylvester Stallone, this lunk-headed backstage drama trades the grit of the first film forslick dance sequencesobviously, somebody saw Famebut it has its charms, especially the overblown, Hell-bound finale sequence.

In the latest tragedy to befall the bloody, shark-plagued legacy of the Brodys, Ellen (Lorraine Gary) is devastated when her son is killed by a great white. Though mourning, she heads to the Bahamas to spend time with her other son, where she falls for Hoagie Newcombe (Michael Caine). But, almost immediately, their budding romance is threatened by another pointy-finned monster from the deep.

RELATED: Steven Spielberg: 5 Reasons Why Jaws Is His Best Monster Movie (& 5 Why Jurassic Park Is A Close Second)

Even a franchise based on an immortal classic isn't immune to the law of diminishing returns,but the Jawssequels went to pot faster than most. Though Jaws 2 and Jaws 3-D have their fans, The Revengeis a last-gasp that few people have warm feelings for. Still, it's entertaining to the ludicrous lengths its makers go to just to justify its existence, and it's easy to see these films in the DNA in such cornball fare as the Sharknado series.

A wheelchair-bound young man and a bug-eyed extraterrestrial form a fast friendship in this legendary turkey from director Stewart Raffill. A hysterically inept and unintentionally creepyE.T. clone with some of the most brazen and extended product placement of all time, Mac and Me is a true case of seeing-is-believing. Treat yourself to theMystery Science Theater 3000 takedown of the movie.The beloved riffing seriesdedicated an episode of The Return to its schlocky, consumerist pleasures.

In the sequel to the 1986 fantasy adventure, Connor MacLeod, the titularwarrior known as the Highlander, has aged after giving up his immortality. After defeating a group of assassins from his homeworld, the Highlander is again granted immortality, leading to a struggle with the cruel General Katana (Michael Ironside).

Highlander(1986) became something of a cult classic despite a mixed critical reception, and The Quickening doublesdown on all the things that may have turned people off in the first film. This more-is-more sequel somehow manages to be more absurd and bombastic than its predecessor, which is either a joy or misery, depending on the viewer.

Avaricious mega corporation Omni Consumer Products is up to their old tricks again, attempting to lay the foundations of the new Delta City to replace a crime-ridden Detroit by enlisting paramilitary forces to relocate residents against their will. An OCP creation now gone rogue, RoboCop (Robert John Burke) joins the civilians in the battle againstthe corporate oppressors and their new state-of-the-art unit of ninja robots.

The RoboCopsequelshavea consistently bad rap, despite being perfectly serviceable, if middling, sci-fi action films. RoboCop 3has theunfortunate distinction of losing the first and second film's hero, Peter Weller, for Robert John Burke, which almost automatically puts it in third place, and, though it's worlds away from the genre-defining classic that spawned it, it's a fine enough time-waster that still manages to touch upon thesocio-economic issues that are RoboCop's bread and butter.

Annie (Sandra Bullock) is in her element when a Caribbean cruise with her boyfriend (Jason Patric) ishijackedby a madman (Willem Dafoe), having survived a bob-rigged bus in 1994's Speed.

RELATED: 5 Action Movies From The 2000s That Are Underrated (& 5 That Are Overrated)

Proving that a bigger budget almost never means better, Speed 2 - Cruise Controlchases the success of the film, before it to no avail. Jason Patric is a poor substitute for Keanu Reeves, but with Willem Dafoe in prime looney-toons mode, Cruise Controlis one of those cable TV staples that simply won't let you change the channel no matter how much you might resist.

In this live-action retelling of the beloved children's tale,a magically animated puppet (Roberto Benigni)sets out on an adventure to rescue his maker and become a flesh and blood boy.

Why Roberto Benigni followed up his Oscar-winning turn in 1997's Life Is Beautiful,which he also wrote and directed, with this monstrosity is a question for the ages, but more people know about it as a cautionary tale than have ever actually seen it. No, Pinocchioisn't good by any stretch, but there's something to be said for experiencing something this misguided and gobsmackingly weird just once.

Retired FBI agent, Jeremiah Ecks (Antonio Banderas) is back on the job after his former cohorts threaten to blackmail him. Tasked with hunting down a DIA operative gone rogue, known only as Sever (Lucy Liu), Ecks soon realizes that the woman he's targeting may be a worthwhile ally against their common enemies.

Rotten Tomatoes has qualified this action disasterpiece as the absolute "most rotten" film of all time, which may disappoint viewers. Ballistic: Ecks vs. Severis terrible, but far more competently made than its infamous RT-approvedlabel would suggest. Come for two big-name actorsembarrassing themselves, stay for the better-than-expected action set pieces.

When Simon (Tyron Leitso) and Greg (Will Sanderson) hook up with a pack of partiers headed for a remote island rave, the last thing they expect to find is zombies, but that's just what they get when they arrive at their destination. The group has to dodge the monsters and get back to safety, which is easier said than done considering that their boat has been swarmedby the undead.

RELATED: 5 Video Game Movie Franchises That Deserve A Reboot (& 5 That Don't)

Uwe Boll is often labeled the "worst director of all time," and, with products like House of the Dead, it's hard to argue.

The male descendants of a cabal of magic-users named the Sons of Ipswich attend an elite boarding school for warlocks. When a student is murdered, the boys start to discover learn more about their shadowy lineage and the family secrets that have been protected for generations.

Renny Harlin's glossyHarry-Potter-by-way-of-Abercrombie-and-Fitch snoozefest is actually something of a guilty-pleasure in queer circles due to its abundance of unintended sexual tension and cast of generic, white, mid-2000s hearth-throbs, including Taylor Kitsch, Sebastian Stan, and Chace Crawford.

NEXT: Rotten Tomatoes: 10 Great Movies With A 'Rotten' Score

Next Disney Villains Ranked By Intelligence

Rocco is a Chicago-based writer, editor, and programmer. An avid devotee of all things weird and outrageous, he's most in his wheelhouse discussing cult oddities and horror classics. Follow him on Instagram: @rosemarys_gayby

Visit link:
10 Of Rotten Tomatoes Worst of All Time That Are Surprisingly Watchable - Screen Rant

Recommendation and review posted by G. Smith

Global Impact of Covid-19 on Glutathione Market to Record Significant Revenue Growth During the Forecast Period 20202028 | KOHJIN Life Sciences,…

Posted: August 13, 2020 at 12:52 pm

Informative Report On Glutathione Market 2020

Glutathionemarket has recently added by Grand View Reportto its massive repository. It offers the continual advancements in technologies which helps to understand the platform for the development of the businesses. It offers numerous strategies for boosting the performance of the companies. Both primary and secondary research techniques carried out to find solutions to different issues faced by various stakeholders.

Top Key Players Profiled in This Report: , Kyowa Hakko Bio, Shandong Jincheng, KOHJIN Life Sciences, Shenzhen GSH Bio-tech, Kaiping Biochemical Pharmaceutical, Gnosis SpA

Glutathione is a very small protein composed of only three amino acids (Glutamate, Glycine, and Cysteine). It is an important antioxidant in plants, animals, fungi, and some bacteria and archaea, preventing damage to important cellular components caused by reactive oxygen species such as free radicals and peroxides. It is can be widely used in pharmaceutical, health products, cosmetic and food additives.

Get a Sample (Use official email ID to Get Higher Priority) Report:https://grandviewreport.com/sample/2366

Covid-19 pandemic affects most industries in the globe. Here at Grand View Report we offer you comprehensive data of related industry which will help and support your business in all possible ways.

Segmentation across regions such as North America, Latin America, Asia-Pacific, Africa, and Europe was undertaken on the basis of productivity. Technological advancements pertaining to the specific market has been studied. Methodologies that can boost the outcome of the businesses have been mentioned in the report.

The Global GlutathioneMarket Can Be Segmented As

The key product type of Glutathionemarket are:, Reduced Glutathione (GSH), Oxidized Glutathione (GSSG)

GlutathioneMarket Outlook by Applications:, Pharmaceuticals, Health Products, Cosmetics, Food, Others

Significant Features that are under Offering and Key Highlights of the Reports:

Exclusive Upto 30% discount:https://grandviewreport.com/discount/2366

Key Questions responded in the report:

Table of Contents:

For More Details On this Report:https://grandviewreport.com/industry-growth/Glutathione-Market-2366

Original post:
Global Impact of Covid-19 on Glutathione Market to Record Significant Revenue Growth During the Forecast Period 20202028 | KOHJIN Life Sciences,...

Recommendation and review posted by G. Smith


Page 6«..5678..2030..»